Want to see HOCPY full AI Analyst Report?
Top Page
HOYA
(OTC:HOCPY)
Select Model
Select Model
Rating:74Outperform
Price Target:
$181.00
▲(20.67% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by very strong financial performance (high profitability, conservative balance sheet, solid cash generation). This is tempered by mixed technical signals (improving short-term trend but weaker longer-term trend and negative MACD) and a relatively high P/E with only a modest dividend yield.
Positive Factors
Conservative balance sheet
HOYA's very low leverage and strong ROE provide durable financial flexibility. Low debt reduces refinancing and solvency risk through downturns, supports opportunistic M&A or R&D funding, and preserves optionality for capital allocation over the next 2-6 months and beyond.
Negative Factors
Uneven revenue & FCF growth
HOYA's revenue and free cash flow have shown volatility across reporting periods, including a near-flat recent annual growth before a TTM rebound. This unevenness complicates planning and may require conservative working capital and investment pacing to avoid profit and cash-flow surprises.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
HOYA's very low leverage and strong ROE provide durable financial flexibility. Low debt reduces refinancing and solvency risk through downturns, supports opportunistic M&A or R&D funding, and preserves optionality for capital allocation over the next 2-6 months and beyond.
Read all positive factors
HOYA (HOCPY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$52.42B
Dividend Yield0.91%
Average Volume (3M)507.00
Price to Earnings (P/E)31.6
Beta (1Y)0.77
Revenue Growth9.10%
EPS Growth27.89%
CountryUS
Employees37,752
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)803.58
Shares Outstanding334,838,000
10 Day Avg. Volume0
30 Day Avg. Volume507
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)9.09
Price to Sales (P/S)9.27
P/FCF Ratio39.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.17
Revenue Forecast (FY)$6.53B
HOYA Business Overview & Revenue Model
Company Description
Established in Tokyo, Japan, in 1941, HOYA Corporation operates as a global med-tech enterprise and a leading provider of advanced technological and medical solutions. Its extensive "life care" division offers a diverse portfolio, ranging from oph...
How the Company Makes Money
HOYA makes money by manufacturing and selling specialized, high-value products across healthcare and technology markets, with revenue primarily generated from product sales (and, where applicable, recurring replacement/consumable demand tied to in...
HOYA Financial Statement Overview
Summary
Income Statement
90
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
87
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 999.52B | 1.00T | 885.82B | 762.61B | 734.10B | 670.33B |
| Gross Profit | 788.61B | 793.79B | 766.25B | 421.69B | 631.86B | 567.28B |
| EBITDA | 407.55B | 359.07B | 310.00B | 285.70B | 259.78B | 243.96B |
| Net Income | 271.52B | 268.35B | 202.10B | 181.38B | 168.64B | 164.51B |
Balance Sheet | ||||||
| Total Assets | 1.29T | 1.31T | 1.23T | 1.20T | 1.03T | 992.84B |
| Cash, Cash Equivalents and Short-Term Investments | 551.83B | 576.58B | 538.53B | 525.16B | 426.27B | 426.63B |
| Total Debt | 45.09B | 42.42B | 37.28B | 29.24B | 24.58B | 21.60B |
| Total Liabilities | 269.43B | 267.05B | 262.65B | 241.36B | 213.72B | 203.78B |
| Stockholders Equity | 1.01T | 1.02T | 974.02B | 967.76B | 818.32B | 803.85B |
Cash Flow | ||||||
| Free Cash Flow | 239.53B | 235.25B | 187.19B | 181.73B | 168.36B | 161.18B |
| Operating Cash Flow | 294.56B | 295.24B | 235.11B | 222.80B | 201.83B | 190.06B |
| Investing Cash Flow | -2.94B | -8.04B | -33.19B | -35.81B | -47.50B | -29.30B |
| Financing Cash Flow | -317.04B | -277.01B | -190.35B | -110.89B | -194.59B | -106.72B |
HOYA Technical Analysis
Negative
149.99
Price Trends
158.98
Negative
166.67
Negative
165.50
Negative
Market Momentum
-0.07
Positive
44.22
Neutral
2.41
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOCPY, the sentiment is Negative. The current price of 149.99 is below the 20-day moving average (MA) of 161.13, below the 50-day MA of 158.98, and below the 200-day MA of 165.50, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 44.22 is Neutral, neither overbought nor oversold. The STOCH value of 2.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HOCPY.
HOYA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $34.13B | 22.58 | 23.88% | 1.23% | 9.85% | 9.65% | |
78 Outperform | $24.52B | 44.46 | 18.51% | 0.27% | 12.42% | 17.07% | |
74 Outperform | $52.42B | 31.57 | 26.25% | 0.95% | 9.10% | 27.89% | |
67 Neutral | $131.36B | 41.86 | 17.83% | ― | 20.66% | 21.06% | |
65 Neutral | $51.69B | 57.29 | 3.79% | 2.39% | -2.56% | -40.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HOCPY
HOYA
156.62
26.70
20.55%
BDX
Becton Dickinson
190.21
40.33
26.91%
ISRG
Intuitive Surgical
370.42
-100.73
-21.38%
RMD
Resmed
235.69
-43.32
-15.53%
WST
West Pharmaceutical Services
349.92
104.72
42.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.